N
Nicole R. LeBoeuf
Researcher at Brigham and Women's Hospital
Publications - 153
Citations - 4477
Nicole R. LeBoeuf is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 20, co-authored 99 publications receiving 3057 citations. Previous affiliations of Nicole R. LeBoeuf include Boston Children's Hospital & Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov,Adi Diab,K. Abdallah,Clifton O. Bingham,C. Brogdon,Ramona Dadu,Lamya Hamad,Sang Taek Kim,Mario E. Lacouture,Nicole R. LeBoeuf,D. Lenihan,C. Onofrei,Vickie R. Shannon,Rajeev Sharma,Ann W. Silk,Dimitra Skondra,Maria E. Suarez-Almazor,Yinghong Wang,K. Wiley,Howard L. Kaufman,Marc S. Ernstoff +20 more
TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Journal ArticleDOI
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids,Haesook T. Kim,Pavan Bachireddy,Caitlin Costello,Rebecca Liguori,Alexandra Savell,Alexander Lukez,David Avigan,Yi-Bin Chen,Peter McSweeney,Nicole R. LeBoeuf,Michael S. Rooney,Michaela Bowden,Chensheng W. Zhou,Scott R. Granter,Jason L. Hornick,Scott J. Rodig,Masahiro Hirakawa,Mariano Severgnini,F. Stephen Hodi,Catherine J. Wu,Catherine J. Wu,Vincent T. Ho,Corey Cutler,John Koreth,Edwin P. Alyea,Joseph H. Antin,Philippe Armand,Howard Streicher,Edward D. Ball,Jerome Ritz,Asad Bashey,Robert J. Soiffer +32 more
TL;DR: Early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred.
Journal ArticleDOI
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Russell W. Jenkins,Amir Reza Aref,Patrick H. Lizotte,Elena Ivanova,Susanna Stinson,Chensheng W. Zhou,Michaela Bowden,Jiehui Deng,Hongye Liu,Diana Miao,Diana Miao,Meng Xiao He,Meng Xiao He,William F. Walker,Gao Zhang,Tian Tian,Chaoran Cheng,Zhi Wei,Sangeetha Palakurthi,Mark A. Bittinger,Hans Vitzthum,Jong Wook Kim,Jong Wook Kim,Ashley A. Merlino,Max M. Quinn,Chandrasekar Venkataramani,Joshua A. Kaplan,Andrew Portell,Prafulla C. Gokhale,Bart Phillips,Alicia Smart,Alicia Smart,Asaf Rotem,Robert E. Jones,Lauren Keogh,Maria Anguiano,Lance Stapleton,Zhiheng Jia,Michal Barzily-Rokni,Israel Cañadas,Tran C. Thai,Marc R. Hammond,Raven Vlahos,Eric S. Wang,Hua Zhang,Shuai Li,Glenn J. Hanna,Wei Huang,Mai P. Hoang,Adriano Piris,Jean Pierre Eliane,Anat Stemmer-Rachamimov,Lisa A. Cameron,Mei-Ju Su,Parin Shah,Benjamin Izar,Benjamin Izar,Manisha Thakuria,Manisha Thakuria,Nicole R. LeBoeuf,Nicole R. LeBoeuf,Guilherme Rabinowits,Viswanath Gunda,Sareh Parangi,James M. Cleary,Brian C. Miller,Shunsuke Kitajima,Rohit Thummalapalli,Benchun Miao,Thanh U. Barbie,Vivek Sivathanu,Joshua A. Wong,William G. Richards,Raphael Bueno,Charles H. Yoon,Juan J. Miret,Meenhard Herlyn,Levi A. Garraway,Eliezer M. Van Allen,Eliezer M. Van Allen,Gordon J. Freeman,Paul Kirschmeier,Jochen H. Lorch,Patrick A. Ott,F. Stephen Hodi,Keith T. Flaherty,Roger D. Kamm,Genevieve M. Boland,Kwok-Kin Wong,David Dornan,Cloud P. Paweletz,David A. Barbie +91 more
TL;DR: The ability to interrogate ex vivo response to PD-1 blockade using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS) is demonstrated, which represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens.
Journal ArticleDOI
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Rachael A. Clark,Rei Watanabe,Jessica E. Teague,Christoph Schlapbach,Marianne Tawa,Natalie Adams,Andrew DoRosario,Keri Chaney,Corey Cutler,Nicole R. LeBoeuf,Joi B. Carter,David C. Fisher,Thomas S. Kupper +12 more
TL;DR: Alemtuzumab destroys the more active malignant cells while sparing the more sessile population, resulting in cancer therapy with retained immunity and, hopefully, the chance for these patients to break many more New Year’s resolutions.
Journal ArticleDOI
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Elizabeth C. Townsend,Mark A. Murakami,Alexandra N. Christodoulou,Amanda L. Christie,Johannes Köster,Tiffany DeSouza,Elizabeth A. Morgan,Scott P. Kallgren,Huiyun Liu,Shuo-Chieh Wu,Olivia Plana,Joan Montero,Kristen E. Stevenson,Prakash Rao,Raga Vadhi,Michael Andreeff,Philippe Armand,Karen K. Ballen,Patrizia Barzaghi-Rinaudo,Sarah Cahill,Rachael A. Clark,Vesselina G. Cooke,Matthew S. Davids,Daniel J. DeAngelo,David M. Dorfman,Hilary Eaton,Benjamin L. Ebert,Julia Etchin,Brant Firestone,David C. Fisher,Arnold S. Freedman,Ilene Galinsky,Hui Gao,Jacqueline S. Garcia,Francine Garnache-Ottou,Timothy A. Graubert,Alejandro Gutierrez,Alejandro Gutierrez,Ensar Halilovic,Marian H. Harris,Zachary T. Herbert,Steven M. Horwitz,Giorgio Inghirami,Andrew M. Intlekofer,Moriko Ito,Shai Izraeli,Eric D. Jacobsen,Caron A. Jacobson,Sébastien Jeay,Irmela Jeremias,Michelle A. Kelliher,Raphael Koch,Marina Konopleva,Nadja Kopp,Steven M. Kornblau,Andrew L. Kung,Thomas S. Kupper,Nicole R. LeBoeuf,Ann S. LaCasce,Emma Lees,Loretta S. Li,A. Thomas Look,Masato Murakami,Markus Müschen,Donna Neuberg,Samuel Y. Ng,Oreofe O. Odejide,Stuart H. Orkin,Rachel R. Paquette,Andrew E. Place,Justine E. Roderick,Jeremy Ryan,Stephen E. Sallan,Brent Shoji,Lewis B. Silverman,Robert J. Soiffer,David P. Steensma,Kimberly Stegmaier,Richard Stone,Jerome Tamburini,Aaron R. Thorner,Paul Van Hummelen,Martha Wadleigh,Marion Wiesmann,Andrew P. Weng,Jens Wuerthner,David A. Williams,Bruce M. Wollison,Andrew A. Lane,Anthony Letai,Monica M. Bertagnolli,Jerome Ritz,Myles Brown,Henry W. Long,Jon C. Aster,Margaret A. Shipp,James D. Griffin,David M. Weinstock,David M. Weinstock +98 more
TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.